Market Runner: Could Insulet Corporation Decline After Today’s Significant Increase?

Market Runner: Could Insulet Corporation Decline After Today's Significant Increase?

The stock of Insulet Corporation (NASDAQ:PODD) is a huge mover today! About 1.53 million shares traded hands or 212.41% up from the average. Insulet Corporation (NASDAQ:PODD) has declined 10.43% since April 4, 2016 and is downtrending. It has underperformed by 11.52% the S&P500.
The move comes after 7 months positive chart setup for the $1.78B company. It was reported on Nov, 4 by We have $47.83 PT which if reached, will make NASDAQ:PODD worth $587.40 million more.

Insulet Corporation (NASDAQ:PODD) Ratings Coverage

Out of 9 analysts covering Insulet Corporation (NASDAQ:PODD), 5 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 56% are positive. Insulet Corporation has been the topic of 17 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, August 4 by Jefferies. Benchmark downgraded Insulet Corporation (NASDAQ:PODD) on Thursday, August 13 to “Hold” rating. The stock of Insulet Corporation (NASDAQ:PODD) earned “Buy” rating by Benchmark on Friday, February 26. Morgan Stanley initiated the shares of PODD in a report on Monday, November 2 with “Equal-Weight” rating. On Friday, April 29 the stock rating was upgraded by William Blair to “Outperform”. The rating was initiated by Empire on Thursday, February 25 with “Sell”. Northland Capital maintained Insulet Corporation (NASDAQ:PODD) on Friday, November 6 with “Outperform” rating.

According to Zacks Investment Research, “INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company’s OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes.”

Insitutional Activity: The institutional sentiment increased to 1.35 in Q2 2016. Its up 0.43, from 0.92 in 2016Q1. The ratio is positive, as 18 funds sold all Insulet Corporation shares owned while 45 reduced positions. 29 funds bought stakes while 56 increased positions. They now own 59.20 million shares or 0.11% less from 59.26 million shares in 2016Q1.
Price T Rowe Assoc Md holds 0% or 189,991 shares in its portfolio. Tributary Capital Mgmt Llc has 0.28% invested in the company for 62,400 shares. Blackrock Japan Ltd owns 489 shares or 0% of their US portfolio. Citadel Advsrs Ltd Llc reported 31,917 shares or 0% of all its holdings. Deutsche Savings Bank Ag has 0.01% invested in the company for 282,212 shares. Teton Advisors last reported 74,084 shares in the company. Pura Vida Limited Liability Corp holds 145,500 shares or 1.87% of its portfolio. Mutual Of America Cap Management Lc, a New York-based fund reported 31,258 shares. Columbus Circle Investors holds 0.01% or 36,081 shares in its portfolio. Parametric Portfolio Associates Limited Liability Corporation, a Washington-based fund reported 33,789 shares. D E Shaw Com owns 701,684 shares or 0.04% of their US portfolio. The Florida-based State Board Of Administration Of Florida Retirement Systems has invested 0% in Insulet Corporation (NASDAQ:PODD). Employees Retirement Association Of Colorado accumulated 0% or 14,692 shares. Marshall Wace Ltd Liability Partnership has 0.01% invested in the company for 21,334 shares. Wells Fargo And Mn last reported 25,555 shares in the company.

Insider Transactions: Since May 5, 2016, the stock had 2 insider purchases, and 1 sale for $1.05 million net activity. SOMMER REGINA O had sold 8,019 shares worth $243,924 on Wednesday, May 25. 1,656 shares with value of $49,890 were bought by Thomas Bradley A on Thursday, May 5. SULLIVAN PATRICK J also bought $1.22 million worth of Insulet Corporation (NASDAQ:PODD) shares.

More notable recent Insulet Corporation (NASDAQ:PODD) news were published by: which released: “Here’s Why Insulet Corporation Is Plunging Today” on November 02, 2016, also with their article: “Insulet Corporation Honors National Diabetes Awareness Month at the NASDAQ …” published on November 01, 2016, published: “Why Insulet Corporation is Soaring Today” on February 26, 2016. More interesting news about Insulet Corporation (NASDAQ:PODD) were released by: and their article: “Why Insulet Corporation and Tandem Diabetes Care Both Tanked Today” published on May 03, 2016 as well as‘s news article titled: “Why Insulet Corporation Shares Are Soaring 19.5% Today” with publication date: August 04, 2016.

PODD Company Profile

Insulet Corporation, incorporated on July 20, 2000, is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Company’s principal offices are located in Billerica, Massachusetts. The OmniPod System features two discreet devices and provides for automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Firm is producing the OmniPod on semi-automated manufacturing lines at a facility in China, operated by a subsidiary of Flextronics International Ltd. (Flextronics). The Firm purchases OmniPods pursuant to its agreement with Flextronics. It also partners with pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. It sells the OmniPod System and other diabetes management supplies in the United States through direct sales to clients or through its distribution partners. The OmniPod System is available in multiple countries in Europe, Canada and Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment